165 related articles for article (PubMed ID: 36633448)
1. TTR (transthyretin) leads the autophagy disaster relief team against TARDBP/TDP-43 proteinopathy.
Chu YP; Ho PC; Tsai KJ
Autophagy; 2023 Aug; 19(8):2403-2405. PubMed ID: 36633448
[TBL] [Abstract][Full Text] [Related]
2. Transthyretin attenuates TDP-43 proteinopathy by autophagy activation via ATF4 in FTLD-TDP.
Chu YP; Jin LW; Wang LC; Ho PC; Wei WY; Tsai KJ
Brain; 2023 May; 146(5):2089-2106. PubMed ID: 36355566
[TBL] [Abstract][Full Text] [Related]
3. Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD.
Wood A; Gurfinkel Y; Polain N; Lamont W; Lyn Rea S
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946763
[TBL] [Abstract][Full Text] [Related]
4. PTK2/FAK regulates UPS impairment via SQSTM1/p62 phosphorylation in TARDBP/TDP-43 proteinopathies.
Lee S; Jeon YM; Cha SJ; Kim S; Kwon Y; Jo M; Jang YN; Lee S; Kim J; Kim SR; Lee KJ; Lee SB; Kim K; Kim HJ
Autophagy; 2020 Aug; 16(8):1396-1412. PubMed ID: 31690171
[TBL] [Abstract][Full Text] [Related]
5. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders.
Janssens J; Van Broeckhoven C
Hum Mol Genet; 2013 Oct; 22(R1):R77-87. PubMed ID: 23900071
[TBL] [Abstract][Full Text] [Related]
6. Intracellular dynamics of Ataxin-2 in the human brains with normal and frontotemporal lobar degeneration with TDP-43 inclusions.
Watanabe R; Higashi S; Nonaka T; Kawakami I; Oshima K; Niizato K; Akiyama H; Yoshida M; Hasegawa M; Arai T
Acta Neuropathol Commun; 2020 Oct; 8(1):176. PubMed ID: 33115537
[TBL] [Abstract][Full Text] [Related]
7. Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies.
Young AL; Vogel JW; Robinson JL; McMillan CT; Ossenkoppele R; Wolk DA; Irwin DJ; Elman L; Grossman M; Lee VMY; Lee EB; Hansson O
Brain; 2023 Jul; 146(7):2975-2988. PubMed ID: 37150879
[TBL] [Abstract][Full Text] [Related]
8. Disease animal models of TDP-43 proteinopathy and their pre-clinical applications.
Liu YC; Chiang PM; Tsai KJ
Int J Mol Sci; 2013 Oct; 14(10):20079-111. PubMed ID: 24113586
[TBL] [Abstract][Full Text] [Related]
9. Withania somnifera Reverses Transactive Response DNA Binding Protein 43 Proteinopathy in a Mouse Model of Amyotrophic Lateral Sclerosis/Frontotemporal Lobar Degeneration.
Dutta K; Patel P; Rahimian R; Phaneuf D; Julien JP
Neurotherapeutics; 2017 Apr; 14(2):447-462. PubMed ID: 27928708
[TBL] [Abstract][Full Text] [Related]
10. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration.
Riku Y; Iwasaki Y; Ishigaki S; Akagi A; Hasegawa M; Nishioka K; Li Y; Riku M; Ikeuchi T; Fujioka Y; Miyahara H; Sone J; Hattori N; Yoshida M; Katsuno M; Sobue G
Brain; 2022 Aug; 145(8):2769-2784. PubMed ID: 35274674
[TBL] [Abstract][Full Text] [Related]
11. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies.
Geser F; Lee VM; Trojanowski JQ
Neuropathology; 2010 Apr; 30(2):103-12. PubMed ID: 20102519
[TBL] [Abstract][Full Text] [Related]
12. TARDBP 3'-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy.
Gitcho MA; Bigio EH; Mishra M; Johnson N; Weintraub S; Mesulam M; Rademakers R; Chakraverty S; Cruchaga C; Morris JC; Goate AM; Cairns NJ
Acta Neuropathol; 2009 Nov; 118(5):633-45. PubMed ID: 19618195
[TBL] [Abstract][Full Text] [Related]
13. Mislocalization of Nup62 Contributes to TDP-43 Proteinopathy in ALS/FTLD.
Nag N; Tripathi T
ACS Chem Neurosci; 2022 Sep; 13(17):2544-2546. PubMed ID: 36001801
[TBL] [Abstract][Full Text] [Related]
14. RNA Binding Proteins and the Pathogenesis of Frontotemporal Lobar Degeneration.
Hofmann JW; Seeley WW; Huang EJ
Annu Rev Pathol; 2019 Jan; 14():469-495. PubMed ID: 30355151
[TBL] [Abstract][Full Text] [Related]
15. Developmentally Regulated RNA-binding Protein 1 (Drb1)/RNA-binding Motif Protein 45 (RBM45), a Nuclear-Cytoplasmic Trafficking Protein, Forms TAR DNA-binding Protein 43 (TDP-43)-mediated Cytoplasmic Aggregates.
Mashiko T; Sakashita E; Kasashima K; Tominaga K; Kuroiwa K; Nozaki Y; Matsuura T; Hamamoto T; Endo H
J Biol Chem; 2016 Jul; 291(29):14996-5007. PubMed ID: 27226551
[TBL] [Abstract][Full Text] [Related]
16. TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis.
Van Deerlin VM; Leverenz JB; Bekris LM; Bird TD; Yuan W; Elman LB; Clay D; Wood EM; Chen-Plotkin AS; Martinez-Lage M; Steinbart E; McCluskey L; Grossman M; Neumann M; Wu IL; Yang WS; Kalb R; Galasko DR; Montine TJ; Trojanowski JQ; Lee VM; Schellenberg GD; Yu CE
Lancet Neurol; 2008 May; 7(5):409-16. PubMed ID: 18396105
[TBL] [Abstract][Full Text] [Related]
17. Towards a TDP-43-Based Biomarker for ALS and FTLD.
Feneberg E; Gray E; Ansorge O; Talbot K; Turner MR
Mol Neurobiol; 2018 Oct; 55(10):7789-7801. PubMed ID: 29460270
[TBL] [Abstract][Full Text] [Related]
18. ALS and FTLD: two faces of TDP-43 proteinopathy.
Liscic RM; Grinberg LT; Zidar J; Gitcho MA; Cairns NJ
Eur J Neurol; 2008 Aug; 15(8):772-80. PubMed ID: 18684309
[TBL] [Abstract][Full Text] [Related]
19. Possible concurrence of TDP-43, tau and other proteins in amyotrophic lateral sclerosis/frontotemporal lobar degeneration.
Takeda T
Neuropathology; 2018 Feb; 38(1):72-81. PubMed ID: 28960544
[TBL] [Abstract][Full Text] [Related]
20. Pathway from TDP-43-Related Pathology to Neuronal Dysfunction in Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration.
Riku Y; Seilhean D; Duyckaerts C; Boluda S; Iguchi Y; Ishigaki S; Iwasaki Y; Yoshida M; Sobue G; Katsuno M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
